SR33805|121345-64-0|-陌孚医药/Medlife

您当前的位置：

SR33805

目录号: PL03642 纯度: ≥99%

CAS No. :121345-64-0

商品编号	规格	价格	会员价
PL03642-5mg	5mg	¥2893.00	请登录
PL03642-10mg	10mg	¥4821.00	请登录
PL03642-50mg	50mg	¥13661.00	请登录
PL03642-100mg	100mg	¥20894.00	请登录
PL03642-200mg	200mg	询价	询价
PL03642-500mg	500mg	询价	询价
PL03642-10mM*1mLinDMSO	10mM*1mLinDMSO	¥3600.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	SR33805
英文名称	SR33805
英文别名	Benzeneethanamine,3,4-dimethoxy-N-methyl-N-[3-[4-[[1-methyl-2-(1-methylethyl)-1H-indol-3-yl]sulfonyl]phenoxy]propyl]-;N-[2-(3,4-dimethoxyphenyl)ethyl]-N-methyl-3-[4-(1-methyl-2-propan-2-ylindol-3-yl)sulfonylphenoxy]propan-1-amine;3,4-Dimethoxy-N-methyl-N(3-(4-((1-methyl-2-(1-methylethyl)-1H-indol-3-yl)sulfonyl)phenoxy)propyl)benzeneethanamine;AC1L2VL6;Benzeneethanamine, 3,4-dimethoxy-N-methyl-N(3-(4-((1-methyl-2-(1-methylethyl)-1H-indol-3-yl)sulfonyl)phenoxy)propyl)-;CHEBI:144947;CHEMBL287679;N-[2-(3,4-dimethoxyphenyl)ethyl]-N-methyl-3-(4-{[1-methyl-2-(propan-2-yl)-1H-indol-3-yl]sulfonyl}phenoxy)propan-1-amine;SR 33805;SR-33805;SureCN7268066;SR33805;3,4-Dimethoxy-N-methyl-N-[3-[4-[[1-methyl-2-(1-methylethyl)-1H-indol-3-yl]sulfonyl]phenoxy]propyl]benzeneethanamine;Benzeneethanamine, 3,4-dimethoxy-N-methyl-N(3-(4-((1-methyl-2-(1
Cas No.	121345-64-0
分子式	C₃₂H₄₀N₂O₅S
分子量	564.74
包装储存	Powder -20°C 3 years；4°C 2 years

产品详情	SR33805 是一种有效的 Ca²⁺ 通道拮抗剂，在去极化和极化条件下的 EC₅₀ 值分别为 4.1 nM 和 33 nM。SR33805 阻止 L 型而不是 T 型 Ca²⁺ 通道。SR33805 可用于研究急性或慢性心脏衰竭。
生物活性	SR33805 is a potent Ca channel antagonist, with EC 50 s of 4.1 nM and 33 nM in depolarized and polarized conditions, respectively. SR33805 blocks L-type but not T-type Ca channels. SR33805 can be used for the research of acute or chronic failing hearts.
性状	Solid
IC50 & Target[1][2]	L-type calcium channel 4.1 nM (EC50, in depolarized conditions) L-type calcium channel
体外研究(In Vitro)	SR33805 (0.01-10 μM; 3 d) inhibits growth factor-induced proliferation of SMC (0.20SR33805 (10 μM; 10 min) restores the myocardial infarction (MI)-altered cell shortening without affecting the Ca transient amplitude. SR33805 (10 μM) decreases the activity of recombinant PKA.
体内研究(In Vivo)	SR33805 (20 mg/kg; a single i.p.) improves end-systolic strain and fractional shortening of MI hearts in rats. SR33805 (5 mg/kg/day; p.o. for 38 d) significantly reduces intimal hyperplasia in pigs. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Powder -20°C 3 years；4°C 2 years
参考文献	[1]. Romey G, et, al. Effects of two chemically related new Ca2+ channel antagonists, SR33557 (fantofarone) and SR33805, on the L-type cardiac channel. Eur J Pharmacol. 1994 Sep 22; 263(1-2): 101-5. [2]. Mou YA, et, al. Beneficial effects of SR33805 in failing myocardium. Cardiovasc Res. 2011 Aug 1; 91(3): 412-9.

溶解度数据	In Vitro: DMSO : ≥ 100 mg/mL (177.07 mM)配制储备液

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation